
Combination of RAS inhibition and immunotherapy provides breakthrough for pancreatic cancer
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to …